Retrospective ED study links two drugs to fewer short-term returns than…
Comparative Effectiveness of Haloperidol, Droperidol, and Ondansetron for Cannabinoid Hyperemesis Syndrome in the Emergency Department.
AI Summary
This multicenter retrospective cohort study compared haloperidol, droperidol, and ondansetron among adults treated in emergency departments for vomiting and cannabis-related diagnoses consistent with suspected cannabinoid hyperemesis syndrome (CHS). The main outcome was returning to the ED within 72 hours. After propensity-score matching, 72-hour returns were less frequent with haloperidol than ondansetron (8.2% vs. 15.1%) and with droperidol than ondansetron (7.4% vs. 14.0%). These are observational associations, not proof that either medication caused fewer returns.
There was no statistically significant difference in 72-hour returns between droperidol and haloperidol. The study also reports that coded adverse events were rare across all medication groups, but it cannot establish comparative safety in detail. Because this was a retrospective study of patients identified through diagnostic codes, it cannot confirm CHS diagnoses or determine the best medication strategy. This is an abstract-based summary; the authors call for prospective studies.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Nausea research papers you might find interesting.
Retrospective cases show different intoxication patterns in children and adults
Survey finds similar cannabis use among rural and urban cancer patients
US survey finds CHS-like symptoms reported by some daily cannabis users
Explore More Research
Stay informed about the latest cannabis science.